stoxline Quote Chart Rank Option Currency Glossary
  
Achilles Therapeutics plc (ACHL)
1.25  0.04 (3.31%)    03-28 16:00
Open: 1.22
High: 1.29
Volume: 277,938
  
Pre. Close: 1.21
Low: 1.19
Market Cap: 51(M)
Technical analysis
2024-03-28 4:49:28 PM
Short term     
Mid term     
Targets 6-month :  1.73 1-year :  2.05
Resists First :  1.48 Second :  1.75
Pivot price 1.21
Supports First :  1.04 Second :  0.87
MAs MA(5) :  1.23 MA(20) :  1.23
MA(100) :  0.98 MA(250) :  0.95
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  65.4 D(3) :  58.1
RSI RSI(14): 53.5
52-week High :  1.75 Low :  0.74
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ACHL ] has closed below upper band by 33.6%. Bollinger Bands are 3.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.29 - 1.3 1.3 - 1.3
Low: 1.18 - 1.18 1.18 - 1.19
Close: 1.24 - 1.25 1.25 - 1.26
Company Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Headline News

Thu, 28 Mar 2024
Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update - Defense World

Wed, 27 Mar 2024
Premarket Mover: Achilles Therapeutics PLC (ACHL) Up 1.61% - InvestorsObserver

Wed, 20 Mar 2024
How Will the Market React to Achilles Therapeutics PLC (ACHL) Stock Getting a Bullish Rating - InvestorsObserver

Wed, 13 Mar 2024
Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update - Defense World

Fri, 08 Mar 2024
Premarket Mover: Achilles Therapeutics PLC (ACHL) Up 1.64% - InvestorsObserver

Mon, 26 Feb 2024
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 41 (M)
Shares Float 18 (M)
Held by Insiders 5.7 (%)
Held by Institutions 53.4 (%)
Shares Short 154 (K)
Shares Short P.Month 10 (K)
Stock Financials
EPS -1.9
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.75
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -22.2 %
Return on Equity (ttm) -42.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.65
Qtrly Earnings Growth 0 %
Operating Cash Flow -54 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -0.66
PEG Ratio -0.2
Price to Book value 0.33
Price to Sales 0
Price to Cash Flow -0.96
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android